LIC Q4 Results 2022
India’s largest insurance company, LIC (Life Insurance Corporation of India) declared its Q4 results on Monday.
LIC’s net profit fell 18% to Rs 2,372 crore for the fourth quarter ended 31 March 2022. The insurance company published a profit of Rs 2,893 crore last year.
The insurance giant’s net premium income rose to Rs 1.44 lakh crore, up 18% for the quarter from Rs 1.22 lakh crore (in the same quarter) last year.
The Board of Directors has proposed a dividend of Rs 1.50 per equity share.
For the newly listed company, this is the first quarter financial results declaration.
More on LIC’s Q4
LIC had earlier announced a behemoth Rs. 21,000 crore initial public offering (IPO) on May 4, with a price band between Rs. 902- Rs. 949 per equity share. LIC listing was a government disinvestment exercise, wherein the GOI sold over 22.13 crore shares or a 3.5% stake
The IPO, much to its fan-fare raised $2.7 billion, with buyers, ranging from sovereign funds in Norway and Singapore, to millions of Indian retail investors. However, it had a tepid listing on the indices and is trading nearly 15% below the cutoff price (since its listing on May 17).
On Monday, LIC's script traded 1.89% higher at Rs 837.05 apiece.
Highlights of LIC Q4 Results 2022
- LIC’s net premium income stood at Rs 1.44 lakh crore, up 18% from Rs.1.2 lakh crores on a yearly based.
- The company declared a dividend of Rs.1.5 per equity share
- LIC shares traded nearly 2% high on account of results today
Misses of LIC Quarterly Results
- LIC reported a dip in profits to Rs. 2,372 crores, down 18% Y-o-Y
- The script has been trading at a discount of 15% since listing
In other news
- LIC’s market capitalization stood at an impressive Rs. 5,29,466 crores
- Its P/E ratio trailed at 183
- LIC’s ROCE and ROE came in at 310% and 81.7%
- The insurance giant has more than 65% of the market share
- LIC offers participating insurance products and other products like ULIP, saving insurance products, term insurance, health insurance, annuity and pension
To read the RA disclaimer, please click here
Research Analyst: Bavadharini KS